Efficacy and safety of levetiracetam in pediatric epilepsy

Elberry, Ahmed A.; Felemban, Rawabi K.; Hareeri, Rawan H.; Kurdi, Sawsan

doi:10.1016/j.jsps.2011.06.001

Cited by 5 publications

(9 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 2 ] In a study of 6–12-year-old children with partial seizures treated with levetiracetam, 45% of them had complete improvement after 7–12 months of follow-up. [ 21 ] In a case series of three children with BCECTS treated with levetiracetam, only one child experienced one seizure; otherwise, all the children were seizure-free. [ 1 ] This study achieved comparable results, in which all cases were seizure-free after six months.…”

Section: Discussionmentioning

confidence: 99%

A comparative study on the efficacy of levetiracetam and carbamazepine in the treatment of rolandic seizures in children: An open-label randomized controlled trial

et al. 2020

View full text Add to dashboard Cite

Objective: This study was performed to investigate whether levetiracetam should be preferred to carbamazepine as a treatment choice for benign childhood epilepsy with centro Temporal spikes (BCECTS), the most common partial epilepsy of childhood. Methods: This randomized clinical trial study included 92 children with rolandic epilepsy aged 4–12 years referred to the Pediatric Neurology Clinic at Imam Hossein Hospital, Isfahan, Iran, from April 2019 to January 2020. Patients were selected consecutively and randomly assigned to two study groups (levetiracetam and carbamazepine groups). Patients were followed and revisited every 2 months for 6 months after starting the medication. The frequency and duration of seizure attacks and drug side effects were recorded before treatment and in bi-monthly visits. Data were analyzed by SPSS software Version 24 using Mann–Whitney U- test and Friedman test. Findings: In our study, the seizure frequency decrease was not significantly different between the two groups; however, patients in both groups showed significantly lower seizure frequency in 2, 4, and 6 months of follow-up compared to starting time. After a follow-up for 6 months, one out of 47 (2.1%) patients using levetiracetam showed intolerance, resulting in changing the medication. In addition, two out of 48 (4.1%) patients in the carbamazepine group had skin rashes. No significant changes had been reported regarding the duration of seizure attacks in both groups after treatment. Conclusion: This study showed encouraging results for using levetiracetam, with acceptable results and fewer side effects for the treatment of children with BCECTS in Iran.

show abstract

Section: Discussionmentioning

confidence: 99%

A comparative study on the efficacy of levetiracetam and carbamazepine in the treatment of rolandic seizures in children: An open-label randomized controlled trial

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Elberry and Associates conducted a study and found that generalized tonic-clonic (59%) and tonic seizure (27%) were the major seizure types when they studied 22 patients. 22 It is quite evident from the results that it took near about 7 months to 1 year for the patients (45%) to become seizure free. Normalized EEG was observed in patients (80%) out of 10 patients.…”

Section: Discussionmentioning

confidence: 91%

Efficacy and Safety of Levetiracetam in Refractory Seizures in Children

Rehman¹,

Noureen²,

Basit³

et al. 2022

PJMHS

View full text Add to dashboard Cite

Objective: To assess efficacy and safety of Levetiracetam (LEV) as add-on therapy in children with refractory seizure. Methodology: This prospective observational cohort study was conducted in the Outpatient Department of Paediatric Neurology, “The Children’s Hospital & Institute of Child Health, Multan”, Pakistan from 15th January 2020 to 14th January 2021. Fifty children of aged 2 months to 14 years of both genders with refractory epilepsy were enrolled and received oral LEV. Data on LEV efficacy and side effects were recorded. The medication was considered as “effective” when all seizures had ceased within 3 months, “partially effective” when seizure frequency was decreased by ≥50% and “ineffective” when seizure frequency was decreased by < 50%.or seizure frequency remain unchanged during a period of 3 month. Results: Out of a total of 50 participants, there were 35 (70.0%) male. Mean age was 4.81±3.79 years while mean age at onset of seizures was 2.51±2.85 years. Most frequent type of seizures was generalized tonic clonic seizures in 19 (38.0%) patients followed by focal clonic seizures in 13 (26.0%) patients. Levetiracetam was effective in 14 (28%) patients, partially effective in 24 (48.0%) and not effective in 12 (24.0%) patients. Conclusion: Levetiracetam as add-on therapy reduced the seizure frequency in 76% of the participants without any significant side effects. Keywords: Levetiracetam, refractory seizure, epilepsy, add-on therapy, efficacy.

show abstract

“…Epilepsy is one of the most widespread noninfectious diseases worldwide and one of the most common dangerous neurological disorders [3][4][5][6][7][8][9]. The highest rate of epilepsy is in the first year of life and decreases to the adult levels at ten years old [10,11].…”

Section: Pharmacovigilancementioning

confidence: 99%

Effect of Pyridoxine on the safety of Levetiracetam in a pediatric population with Epilepsy - A Retrospective pharmacovigilance study

Alqweai

ElAwady

Hussein

et al. 2023

Fayoum University Medical Journal

View full text Add to dashboard Cite

Introduction: Epilepsy is one of the most common neurological disorders affecting children. Levetiracetam (LEV) is a widely used anti-epileptic drug (AED) with good pharmacokinetics and a low risk of side effects. Pyridoxine (vitamin B6) is one of the effective additional therapies used to prevent and treat the adverse effects of LEV in children. Aim of the study:The study's goal was to see how pyridoxine affects the safety of LEV therapy in a pediatric epilepsy population. Subjects and Methods:A retrospective study on pediatric patients was conducted at Egypt's Fayoum University Hospital. Thirty patients were selected. The age range of patients receiving LEV as monotherapy ranged from 6 months to 11 years. Patients were divided into two groups: those who only received LEV and those who received LVE plus pyridoxine. The causality and severity of adverse drug reactions (ADRs) were evaluated.Results: ADRs were reported by 71.4% of LEV patients, but only 18.8% of LEV plus pyridoxine patients. These ADRs involved various systems, with 50% involving gastrointestinal symptoms that were significantly p0.006 higher in the LEV group compared to the LEV + Pyridoxine group. In the LEV group, 35.7% had behavioral ADRs that were significantly p0.008 higher. Other neurological side effects were observed. The WHO-UMC criteria for assessing the causality of ADRs revealed that 20% were probable and 23.3% were possible. All of the ADRs were common. Conclusion:The current study found that pyridoxine can help control some ADRs caused by LEV in children.

show abstract

Efficacy and safety of levetiracetam in pediatric epilepsy

Abstract: Our results confirm that LEV may be an effective adjunctive therapy in treatment of childhood epilepsy, especially tonic-clonic seizure, with possible no evident side effect.

Cited by 5 publications

References 18 publications

A comparative study on the efficacy of levetiracetam and carbamazepine in the treatment of rolandic seizures in children: An open-label randomized controlled trial

A comparative study on the efficacy of levetiracetam and carbamazepine in the treatment of rolandic seizures in children: An open-label randomized controlled trial

Efficacy and Safety of Levetiracetam in Refractory Seizures in Children

Effect of Pyridoxine on the safety of Levetiracetam in a pediatric population with Epilepsy - A Retrospective pharmacovigilance study

Contact Info

Product

Resources

About